Submission of Standalone audited financial results for the year ended 31st March, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
KMS Medisurgi Ltd's board approved its audited standalone financial results for FY25 (year ended March 31, 2025) on May 30, 2025. Total income stood at Rs. 1,396.73 lakhs vs Rs. 1,397.77 lakhs in FY24, essentially flat. Revenue from operations rose marginally to Rs. 1,393.86 lakhs from Rs. 1,388.46 lakhs. Net profit came in at Rs. 43.98 lakhs, slightly down from Rs. 45.39 lakhs last year, with EPS at Rs. 1.33 vs Rs. 1.38. The statutory auditor (H H Dedhia & Associates) issued a qualified opinion, flagging two issues: post-employment benefits accounted on LIC's group gratuity basis instead of an actuarial valuation as required by AS-15, and unreconciled stock records where the auditor could not verify the Rs. 252.24 lakh closing inventory. Both qualifications are repetitive from prior years and their financial impact remains unquantified.
Flat revenue and a slight dip in profit indicate weak operating performance, while the repeated qualified opinion on employee benefit accounting and inventory reconciliation raises governance and internal control concerns that investors should monitor. These unresolved audit qualifications may weigh on investor confidence until the company moves to actuarial-based valuations and completes its stock record reconciliation.